R&D News | pharmaphorum

News

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.

News

Our round-up of biotech financings is headed by Encoded, which has raised $275m to advance its gene therapy for Dravet syndrome into pivotal trials.

News

Two senior figures in Canada's life science sector have said they see scope for greater collaboration with the UK following clinical trial reforms.

News

Amgen's Imdelltra and AstraZeneca's Imfinzi have improved survival compared to Imfinzi alone as first-line maintenance treatment for ES-SCLC.

News

BMS' arlo-cel has shown activity in a trial that could underpin filings in multiple myeloma settings where the four main drug classes have failed.

News

The FDA has started a priority review of AstraZeneca's first-in-class IL-33 inhibitor tozorakimab for COPD, setting up a decision in Q1 of 2027.